Ponatinib-associated panniculitis: Case report and review of the literature.

Authors :: Antwi-Amoabeng D
Ghuman J
Ghuman J
Beutler BD
Ulanja MB
Kuriakose K
Bowman A
Source :: Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 27, pp. 100357. Date of Electronic Publication: 2021 Mar 17.
Publication Year :: 2021
Abstract: Ponatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and hypertension. We describe a 49-year-old woman who developed panniculitis after brief treatment with ponatinib. In addition, we summarize other studies describing TKI-associated panniculitis.<br /> (Copyright © 2021. Published by Elsevier Ltd.)